US2018291049A1PendingUtilityA1
Crystalline Forms of Fosnetupitant
Est. expiryOct 6, 2035(~9.2 yrs left)· nominal 20-yr term from priority
A61P 1/08C07F 9/650952C07F 9/091C07B 2200/13A61K 31/675C07F 9/65583C07F 9/650958
49
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention provides crystalline forms of the chloride monohydrochloride salt of fosnetupitant, methods of making the crystalline forms, and pharmaceutical dosage forms that make use of the crystalline forms.
Claims
exact text as granted — not AI-modified1 - 38 ) (canceled)
39 ) Amorphous (4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methylpiperazin-1-ium-1-yl)methyl hydrogen phosphate (fosnetupitant) chloride hydrochloride.
40 ) A pharmaceutical composition comprising the amorphous fosnetupitant chloride hydrochloride of claim 39 and one or more pharmaceutically acceptable excipients.
41 ) A pharmaceutical composition comprising the amorphous fosnetupitant chloride hydrochloride of claim 39 , palonosetron hydrochloride, and one or more pharmaceutically acceptable excipients.
42 ) A composition comprising the amorphous fosnetupitant chloride hydrochloride of claim 39 and Form I fosnetupitant chloride hydrochloride.
43 ) A pharmaceutical composition comprising the amorphous fosnetupitant chloride hydrochloride of claim 39 , Form I fosnetupitant chloride hydrochloride, and palonosetron hydrochloride.Join the waitlist — get patent alerts
Track US2018291049A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.